Together, these results suggest that myCAF is an oncogenic biomarker for advanced ICC stages and poor prognosis, and targeting Has2, TGFβ, or other key regulators that can disturb the interaction between myCAF and other cell types may offer strong therapeutic effects. Here, HAS2 is linked to intrahepatic cholangiocarcinoma.